Drastic Response of Rechallenge of Nivolumab in a Patient with NSCLC Who Progressed on the First Nivolumab Treatment

J Thorac Oncol. 2020 Jan;15(1):e20-e22. doi: 10.1016/j.jtho.2019.10.012.

Affiliations

¹ Department of Medical Oncology, Funabashi Municipal Medical Center, Chiba, Japan. Electronic address: [email protected].
² Department of Respiratory Medicine, Funabashi Municipal Medical Center, Chiba, Japan.
³ Department of Palliative Care Medicine, Funabashi Municipal Medical Center, Chiba, Japan.
⁴ Department of Pathology, Funabashi Municipal Medical Center, Chiba, Japan.

PMID: 31864556
DOI: 10.1016/j.jtho.2019.10.012

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Antineoplastic Agents, Immunological* / adverse effects
Carcinoma, Non-Small-Cell Lung* / drug therapy
Humans
Lung Neoplasms* / drug therapy
Nivolumab / therapeutic use

Substances

Antineoplastic Agents, Immunological
Nivolumab